<DOC>
	<DOC>NCT00817687</DOC>
	<brief_summary>This 2 arm study will evaluate the impact on fibrosis at week 52 of an early biopsy, in patients who have received a kidney transplant from an expanded criteria donor. Patients will be randomized to one of two groups; the first group will have a biopsy at day 10, and the second group will receive standard management. All patients will be given CellCept as standard of care. The anticipated time on study treatment is 1 year, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of the Impact of an Early Biopsy in Patients Treated With CellCept (Mycophenolate Mofetil) After Kidney Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>adult patients, &gt;=18 years of age; in receipt of an initial cadaveric kidney transplant; in receipt of graft with biopsy; in receipt of a 'marginal' kidney transplant. in receipt of a second kidney transplant; in receipt of a multiorgan transplant or a double kidney transplant; malignant tumor, or a history of cancer in past 5 years, other than successfully treated basal cell or spinocellular cancer or cancer in situ of cervix; replicating hepatitis B and/or C, or HIV positive serology.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>